In this viewpoint, authors Francesca Chiara (Senior Advisor, Drug Resistant Infections Programme, Wellcome); Moska Hellamand (Researcher, Access to Medicine Foundation); and Margo Warren (Government Engagement and Policy Manager, Access to Medicine Foundation) make the case for pharmaceutical companies to share surveillance data sets publicly, including and through the AMR Register.
This viewpoint covers:
The current landscape of drug surveillance
How drug surveillance is currently gathered and used in both the public and private sectors
How data from pharmaceutical companies is valuable in furthering understanding of drug resistance
How combining surveillance data can improve research and development outcomes
How the Access to Medicine Foundation and Wellcome's Drug Resistant Infections Team are working together to promote transparency and the wider use of industry data